Company Overview - NLS Pharmaceutics is a global development-stage biopharmaceutical company focused on innovative therapies for rare and complex central nervous system disorders [4] - Kadimastem is a clinical stage cell therapy company developing proprietary cell products for various neurodegenerative conditions [5][6] Merger Details - NLS has successfully closed an initial $500,000 from a $1 million fundraising round at a share price of $3.10, which is a 48% increase above the market price at the time [1] - The merger with Kadimastem aims to create a combined Nasdaq-traded biotechnology company with a strong pipeline of advanced therapies [1][3] - NLS has filed an F-4 Registration Statement with the SEC detailing the proposed merger [2] Leadership Statements - Alex Zwyer, CEO of NLS, expressed excitement about the merger, highlighting its potential to enhance shareholder value and redefine the biotechnology landscape [3] - Ronen Twito, CEO of Kadimastem, emphasized the merger's potential to create a powerful entity in the biotechnology sector and unlock new growth opportunities [3]

Core Viewpoint - The proposed merger between NLS Pharmaceutics and Kadimastem will result in Kadimastem becoming a wholly owned subsidiary of NLS, with Kadimastem shareholders holding approximately 85% of the combined company post-transaction [1][9]. Company Overview - NLS Pharmaceutics is a global development-stage biopharmaceutical company focused on innovative therapies for rare and complex central nervous system disorders, headquartered in Switzerland [18]. - Kadimastem is a clinical-stage cell therapy company developing proprietary cell products based on human embryonic stem cells, with its lead product, AstroRx®, in clinical development for ALS [11][19]. Transaction Details - The merger has been approved by the boards of directors of both companies, with over 40% of shareholders committed to supporting the merger [17]. - NLS will issue common shares to Kadimastem shareholders as part of the transaction, resulting in existing NLS shareholders retaining 15% of the company [1][9]. - The merger is subject to shareholder approvals and regulatory requirements, including the SEC's declaration of the Registration Statement as effective [15]. Strategic Objectives - The merger is seen as a crucial milestone for both companies, aimed at unlocking the potential of their innovative technologies and enhancing shareholder value through expanded growth opportunities [3][9]. - Post-merger, the companies plan to continue developing NLS's Dual Orexin Agonist platform, while divesting remaining NLS assets under a contingent value rights agreement [9].

Exhibit 99.1 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Interim Condensed Balance Sheets as of June 30, 2024 (unaudited) and Decembe ...

Core Viewpoint - The merger agreement between NLS Pharmaceutics and Kadimastem will result in Kadimastem investors acquiring 85% of the combined company's stock, with the new entity operating under the Kadimastem name [1] Group 1: Merger Details - NLS Pharmaceutics will be acquired by a wholly-owned subsidiary of Kadimastem, leading to a significant ownership shift [1] - The merger is expected to be executed in September, with a closing date anticipated by the end of the year [3] - Following the merger, nearly all members of the NLS Pharmaceutics board and executive team will depart, except for one [6] Group 2: Stock Market Impact - NLS Pharmaceutics stock has seen a substantial increase of 47.8% as of Monday morning following the merger announcement [7] - Heavy trading activity has been noted, with over 98 million shares being traded, significantly higher than the average daily volume of about 10 million shares [4][5] Group 3: Future Developments - The combined company will continue to develop NLS Pharmaceutics' Dual Orexin Agonist platform and Kadimastem's allogeneic cell products [6] - NLS shareholders will have the opportunity to benefit from the equity of the merged company and the value of legacy assets through a contingent value rights agreement [7]

Group 1 - NLS Pharmaceutics (NASDAQ:NLSP) stock experienced a significant rally of 82.1% on Tuesday, with over 302 million shares traded, compared to its daily average of 6.5 million shares [1][2] - The rally occurred without any clear news from the company, indicating that speculative trading may have driven the price increase, particularly as NLSP is classified as a penny stock, making it susceptible to manipulation [2] - As of Thursday morning, NLSP stock is down 22.6%, and it has decreased by 54.2% since the beginning of the year [3]

PART I [Key Information](index=9&type=section&id=ITEM%203.%20KEY%20INFORMATION.) The company's investment profile is marked by significant risks in business operations, financial stability, and regulatory compliance [Risk Factors](index=9&type=section&id=D.%20Risk%20Factors.) The company faces substantial risks from its product dependency, financial losses, capital needs, and internal control weaknesses - The company's 2023 financial statements include a **"going concern" disclosure**, with an accumulated deficit of approximately **$70.4 million**[48](index=48&type=chunk)[121](index=121&type=chunk) - NLS is heavily dependent on the success of its two main product candidates, **Quilience and Nolazol**, and failure to obtain regulatory approval would severely harm the business[43](index=43&type=chunk)[51](index=51&type=chunk) - The company relies on a **single manufacturer for its mazindol drug substance**, posing significant supply chain risk[48](index=48&type=chunk)[140](index=140&type=chunk) - **Material weaknesses** were identified in internal financial controls due to insufficient trained accounting professionals and a lack of appropriate segregation of duties[182](index=182&type=chunk)[184](index=184&type=chunk) - The company has received **delisting warnings from Nasdaq** for failing to meet minimum bid price and stockholders' equity requirements[190](index=190&type=chunk)[192](index=192&type=chunk) [Information on the Company](index=52&type=section&id=ITEM%204.%20INFORMATION%20ON%20THE%20COMPANY.) The company is a clinical-stage biopharmaceutical firm focused on developing therapies for rare CNS disorders using its lead compound, Mazindol ER [History and Development of the Company](index=52&type=section&id=A.%20History%20and%20Development%20of%20the%20Company.) Established in 2015, the company operates as an emerging growth company and foreign private issuer under SEC rules - The company was established on June 10, 2015, and acquired patents for its lead compound mazindol in 2016 from Assistance Publique - Hopitaux de Paris (AP-HP)[226](index=226&type=chunk)[227](index=227&type=chunk) - It qualifies as an **"emerging growth company"** and **"foreign private issuer"**, granting it exemptions from certain SEC reporting and governance requirements[229](index=229&type=chunk)[230](index=230&type=chunk) [Business Overview](index=53&type=section&id=B.%20Business%20Overview.) The company's pipeline is led by Quilience (Mazindol ER) for narcolepsy, with Nolazol for ADHD and other earlier-stage compounds - The company's lead product candidate is **Quilience (Mazindol ER)** for the treatment of narcolepsy, with a Phase 2 trial showing positive results[235](index=235&type=chunk)[249](index=249&type=chunk) - The follow-on candidate, **Nolazol (Mazindol ER)** for ADHD, has completed a Phase 2 trial, but further development is on hold[235](index=235&type=chunk) - Mazindol has a unique dual mechanism of action as a triple monoamine reuptake inhibitor and a partial **orexin receptor 2 (OX2R) agonist**[233](index=233&type=chunk)[237](index=237&type=chunk)[239](index=239&type=chunk) - In March 2024, NLS secured an exclusive global license for Aexon Labs' **Dual Orexin Receptor Agonists platform** of over 300 new molecular entities[355](index=355&type=chunk)[356](index=356&type=chunk) - The research pipeline includes **NLS-4 for chronic fatigue associated with Long-COVID**, NLS-3 for ADHD, and other compounds for cognitive improvement[345](index=345&type=chunk)[349](index=349&type=chunk)[350](index=350&type=chunk) [Organizational Structure](index=93&type=section&id=C.%20Organizational%20Structure.) NLS Pharmaceutics Ltd is a Swiss stock corporation with a wholly owned U.S. subsidiary, NLS Pharmaceutics Inc - The company is a Swiss stock corporation headquartered in Zurich, Switzerland[388](index=388&type=chunk) - It has a wholly owned U.S. subsidiary, NLS Pharmaceutics Inc, which was incorporated in Delaware in April 2021[389](index=389&type=chunk) [Property, Plant and Equipment](index=93&type=section&id=D.%20Property%2C%20Plant%20and%20Equipment.) The company leases approximately 270 square feet of shared office space in Zurich, which management considers sufficient - The company leases approximately **270 square feet** of shared office space in Zurich, Switzerland, which it deems sufficient for its current operations[390](index=390&type=chunk)[391](index=391&type=chunk) [Operating and Financial Review and Prospects](index=93&type=section&id=ITEM%205.%20OPERATING%20AND%20FINANCIAL%20REVIEW%20AND%20PROSPECTS.) The company reported a lower net loss of $12.2 million in 2023, but its low cash balance raises substantial doubt about its going concern status [Operating Results](index=96&type=section&id=A.%20Operating%20Results.) The net loss for 2023 decreased to $12.2 million from $16.5 million in 2022, driven by a 34.2% reduction in R&D expenses | | For the Year Ended December 31, | | |---|---|---| | | **2023** | **2022** | | Research and development expenses | $5,908,288 | $8,976,643 | | General and administrative expenses | $5,898,775 | $6,505,721 | | **Operating loss** | **($11,807,063)** | **($15,482,364)** | | **Net loss** | **($12,172,029)** | **($16,495,680)** | - The significant decrease in R&D expenses in 2023 was attributed to the absence of active clinical trials during the year[428](index=428&type=chunk) - The decrease in G&A expenses was due to lower costs for directors and officers insurance, accounting services, and legal counsel[429](index=429&type=chunk) [Liquidity and Capital Resources](index=99&type=section&id=B.%20Liquidity%20and%20Capital%20Resources.) Cash and cash equivalents fell to $0.9 million at year-end 2023, an amount insufficient to fund operations for the next year - The company's cash and cash equivalents decreased to **$0.9 million** as of December 31, 2023, from $8.9 million as of December 31, 2022[396](index=396&type=chunk)[436](index=436&type=chunk) - Management has concluded that existing cash is not sufficient to fund operations for one year, raising **substantial doubt about the company's ability to continue as a going concern**[396](index=396&type=chunk)[440](index=440&type=chunk)[447](index=447&type=chunk) | Cash Flow Summary | 2023 | 2022 | |---|---|---| | Net cash used in operating activities | $(9,684,466) | $(13,879,371) | | Net cash used in investing activities | $0 | $0 | | Net cash provided by financing activities | $1,633,746 | $17,396,669 | - Financing activities in 2023 consisted of **$1.6 million in proceeds from short-term loans** from existing shareholders[442](index=442&type=chunk) [Critical Accounting Estimates](index=102&type=section&id=E.%20Critical%20Accounting%20Estimates.) Key accounting estimates involve deferred revenue from a license agreement, pension obligations, and a full valuation allowance on deferred tax assets - Revenue from the Eurofarma License Agreement, including a **$2.5 million upfront payment, remains deferred** as of December 31, 2023[459](index=459&type=chunk) - The company maintains a **full valuation allowance** against its deferred tax assets due to a history of losses and uncertainty about future profitability[461](index=461&type=chunk)[709](index=709&type=chunk) [Directors, Senior Management and Employees](index=103&type=section&id=ITEM%206.%20DIRECTORS%2C%20SENIOR%20MANAGEMENT%20AND%20EMPLOYEES.) The company's leadership includes a six-member board and key executives, with total 2023 compensation for management at $2.0 million [Directors and Senior Management](index=103&type=section&id=A.%20Directors%20and%20Senior%20Management.) The leadership team includes the CEO, CFO, CMO, and CSO, overseen by a six-member board of directors elected for one-year terms - The board of directors consists of six members: Ronald Hafner (Chairman), Alexander Zwyer (CEO), Florence Allouche Aknin, Claudio L. A. Bassetti, Audrey Greenberg, and Gian-Marco Rinaldi[462](index=462&type=chunk)[484](index=484&type=chunk) [Compensation](index=106&type=section&id=B.%20Compensation.) Aggregate compensation for all directors and senior management was approximately $2.0 million in 2023 | Compensation for All Directors and Senior Management (10 persons) - 2023 | Amount (in thousands) | |---|---| | Salary, Bonuses and Related Benefits | $1,631 | | Pension, Retirement and Other Similar Benefits | $111 | | Share Based Compensation | $272 | | **Total** | **$2,014** | [Board Practices](index=107&type=section&id=C.%20Board%20Practices.) The board has five independent directors and two standing committees, following Swiss home country governance practices for certain rules - The board has determined that **five of its six directors are independent** under Nasdaq rules[486](index=486&type=chunk) - The board has an Audit Committee and a Compensation, Nomination and Governance Committee[487](index=487&type=chunk) - The company follows **Swiss home country rules** for its compensation and nomination committee practices, which vary from Nasdaq listing rules[491](index=491&type=chunk)[492](index=492&type=chunk) [Major Shareholders and Related Party Transactions](index=110&type=section&id=ITEM%207.%20MAJOR%20SHAREHOLDERS%20AND%20RELATED%20PARTY%20TRANSACTIONS.) Major shareholders include BVF Partners L.P. (26.5%), with related party transactions consisting of management agreements and director loans [Major Shareholders](index=110&type=section&id=A.%20Major%20Shareholders.) As of May 2024, the largest shareholder is BVF Partners L.P. with 26.5%, while all directors and management as a group own 14.8% | Holder | Percentage Owned (%) | |---|---| | BVF Partners L.P. | 26.5% | | Lind Global Fund II LP | 9.9% | | YA II PN, Ltd. | 9.1% | | Felix Grisard | 7.5% | | Magnetic Rock Investment AG | 6.6% | | All directors and senior management as a group | 14.8% | [Related Party Transactions](index=111&type=section&id=B.%20Related%20Party%20Transactions.) The company has employment and consulting agreements with senior management and has received short-term loans from directors - The company has employment agreements with its CEO, Alexander Zwyer, and CMO, George Apostol, and consulting agreements with its CSO, Eric Konofal[503](index=503&type=chunk)[505](index=505&type=chunk)[506](index=506&type=chunk)[507](index=507&type=chunk) - The company has entered into **short-term loan agreements** with directors and major shareholders to provide working capital[509](index=509&type=chunk) [Financial Information](index=112&type=section&id=ITEM%208.%20FINANCIAL%20INFORMATION.) The company faces demands for over $2.2 million in unpaid service fees from vendors and has no history of paying dividends - The company has received demands for payment for services rendered from multiple vendors including **Cambrex Corporation ($492,723)**, **Clinilabs, Inc. ($793,112)**, and **CoreRX, Inc. ($1,007,701)**[513](index=513&type=chunk)[514](index=514&type=chunk)[515](index=515&type=chunk) - The company has **never declared or paid cash dividends** and does not intend to in the foreseeable future, subject to Swiss law restrictions[516](index=516&type=chunk)[517](index=517&type=chunk) [Additional Information](index=114&type=section&id=ITEM%2010.%20ADDITIONAL%20INFORMATION.) As a Swiss corporation, shareholders are subject to a 35% withholding tax on dividends and potential classification as a PFIC for U.S. holders - As a Swiss corporation, dividends are generally subject to a **35% Swiss federal withholding tax**, though refunds may be available under tax treaties[205](index=205&type=chunk)[534](index=534&type=chunk) - There is a risk that the company could be classified as a **Passive Foreign Investment Company (PFIC)** for U.S. tax purposes, which could result in adverse tax consequences for U.S. Holders[187](index=187&type=chunk)[571](index=571&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=125&type=section&id=ITEM%2011.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK.) The company's primary market risk is foreign currency exposure, as 33% of its 2023 expenses were in CHF and EUR - The company is exposed to foreign currency exchange risk, with about **26% of its 2023 expenses in CHF and 7% in EUR**[595](index=595&type=chunk) - The company does not currently engage in formal currency hedging transactions[596](index=596&type=chunk) PART II [Controls and Procedures](index=126&type=section&id=ITEM%2015.%20CONTROLS%20AND%20PROCEDURES.) Disclosure controls were deemed ineffective as of year-end 2023 due to material weaknesses in internal financial reporting controls - Management concluded that disclosure controls and procedures were **not effective** as of December 31, 2023, due to material weaknesses in internal control[605](index=605&type=chunk)[610](index=610&type=chunk) - Identified material weaknesses include a **lack of sufficient U.S. GAAP-trained professionals** and a lack of appropriate segregation of duties[609](index=609&type=chunk) - Remediation steps taken during 2023 include **insourcing accounting processes** and appointing a new Chief Financial Officer[612](index=612&type=chunk) [Other Items](index=127&type=section&id=ITEM%2016.%20Other%20Items) Key disclosures include the change of the certifying accountant and details of the company's cybersecurity risk management program [Principal Accountant Fees and Services](index=128&type=section&id=ITEM%2016C.%20PRINCIPAL%20ACCOUNTANT%20FEES%20AND%20SERVICES.) Fees billed by PricewaterhouseCoopers AG totaled $332,690 in 2023 and $330,015 in 2022, exclusively for audit services | Fee Type | 2023 | 2022 | |---|---|---| | Audit fees | $332,690 | $330,015 | | Audit-related fees | $0 | $0 | | Tax fees | $0 | $0 | | All other fees | $0 | $0 | | **Total** | **$332,690** | **$330,015** | [Change in Registrant's Certifying Accountant](index=128&type=section&id=ITEM%2016F.%20CHANGE%20IN%20REGISTRANT'S%20CERTIFYING%20ACCOUNTANT.) PricewaterhouseCoopers AG notified the company it will decline to stand for re-election as the independent auditor - **PricewaterhouseCoopers AG** notified the company on May 15, 2024, that it will not stand for re-election as the company's auditor[619](index=619&type=chunk) - PwC's audit report for FY 2023 included an explanatory paragraph about the company's ability to continue as a **going concern**[620](index=620&type=chunk) - There were **no disagreements** between the company and PwC on any matter of accounting principles or practices during the past two fiscal years[621](index=621&type=chunk) [Corporate Governance](index=128&type=section&id=ITEM%2016G.%20CORPORATE%20GOVERNANCE.) As a foreign private issuer, the company follows Swiss home country governance practices in lieu of certain Nasdaq requirements - The company, as a foreign private issuer, elects to follow **Swiss law** instead of certain Nasdaq corporate governance rules[625](index=625&type=chunk) - Key differences include not requiring a majority-independent board and following Swiss law for compensation and nomination committee practices[626](index=626&type=chunk)[627](index=627&type=chunk) [Cybersecurity](index=131&type=section&id=ITEM%2016K.%20CYBERSECURITY.) Cybersecurity risk management is overseen by the audit committee and integrated into the company's overall risk management program - The **audit committee oversees cybersecurity risk management**, which is integrated into the company's overall risk management program[631](index=631&type=chunk)[634](index=634&type=chunk) - The company has **not experienced any cybersecurity attacks** that have materially affected its business, strategy, or financial condition[635](index=635&type=chunk) PART III [Financial Statements](index=133&type=section&id=ITEM%2018.%20FINANCIAL%20STATEMENTS.) The audited financial statements reflect the company's clinical-stage status and include a going concern warning from the auditor [Report of Independent Registered Public Accounting Firm](index=138&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) The auditor's report highlights substantial doubt about the company's ability to continue as a going concern due to operating losses - The auditor's report contains a paragraph expressing **substantial doubt about the Company's ability to continue as a going concern**, citing operating losses and insufficient cash[653](index=653&type=chunk) [Financial Statements Data](index=139&type=section&id=Financial%20Statements%20Data) The company's financial position deteriorated in 2023, with total liabilities of $10.7 million exceeding total assets of $1.8 million | Balance Sheet Highlights | Dec 31, 2023 | Dec 31, 2022 | |---|---|---| | Cash and cash equivalents | $897,680 | $8,948,400 | | Total assets | $1,846,641 | $9,276,643 | | Total liabilities | $10,680,204 | $5,995,804 | | Total shareholders' equity (deficit) | $(8,833,563) | $3,280,839 | | Statement of Operations Highlights | Year Ended Dec 31, 2023 | Year Ended Dec 31, 2022 | |---|---|---| | Total operating expenses | $11,807,063 | $15,482,364 | | Net loss | $(12,172,029) | $(16,495,680) | | Basic and diluted net loss per common share | $(0.32) | $(0.84) | [Notes to Financial Statements](index=144&type=section&id=Notes%20to%20Financial%20Statements) Notes reiterate the going concern issue, detail deferred revenue, and outline commitments, contingencies, and recent financing activities - The company's cash of **$0.9 million** as of Dec 31, 2023, is not sufficient to fund operations for one year, raising substantial doubt about its ability to continue as a **going concern**[675](index=675&type=chunk) - The company has commitments for potential milestone payments to Novartis, including **$750,000** following an end-of-Phase 2 FDA meeting and **$2 million** upon marketing authorization[756](index=756&type=chunk) - The company has received demands for unpaid services from **Cambrex ($492,723)**, **Clinilabs ($793,112)**, and **CoreRX ($1,007,701)**[758](index=758&type=chunk)[759](index=759&type=chunk)[760](index=760&type=chunk) - In March 2024, the company closed a registered direct offering for gross proceeds of **$1.75 million** by selling 7 million common shares at $0.25 per share[808](index=808&type=chunk)

[Report of Foreign Private Issuer on Form 6-K](index=1&type=section&id=Report%20of%20Foreign%20Private%20Issuer%20on%20Form%206-K) [Management Change](index=2&type=section&id=Management%20Change) Mr. Chad Hellmann resigned as CFO of NLS Pharmaceutics Ltd. on May 1, 2023, providing transition services until May 31, 2023 - Mr. Chad Hellmann resigned as the **Chief Financial Officer** on **May 1, 2023**[4](index=4&type=chunk) - Mr. Hellmann will provide transition services to the company through **May 31, 2023**[4](index=4&type=chunk) - The resignation was **not based on any material disagreement** with the company on any matter relating to its operations, policies, or practice[4](index=4&type=chunk) [Incorporation by Reference](index=2&type=section&id=Incorporation%20by%20Reference) This Form 6-K report is incorporated by reference into the company's Registration Statements on Form F-3, including specified file numbers - The Form 6-K is **incorporated by reference** into the Registrant's Registration Statements on **Form F-3** with file numbers **333-262489**, **333-268690**, and **333-269220**[5](index=5&type=chunk) [Signatures](index=3&type=section&id=SIGNATURES) The report was duly authorized and signed on May 5, 2023, by Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics Ltd - The report was signed on **May 5, 2023**, by **Alexander Zwyer**, **Chief Executive Officer**[9](index=9&type=chunk)

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 001-39957 NLS PHARMACEUTICS LTD. (Exact name of registrant ...

| Unaudited Interim Condensed Balance Sheets as of June 30, 2022 and December 31, 2021 | 1 | | --- | --- | | Unaudited Interim Condensed Statements of Operating and Comprehensive Loss for the Six Months Ended June 30, 2022 | 2 | | and 2021 | | | Unaudited Interim Condensed Statements of Changes in Equity for the Six Months Ended June 30, 2022 and 2021 | 3 | | Unaudited Interim Condensed Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 | 4 | | Notes to the Unaudited Interim Condensed ...

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 001-39957 NLS PHARMACEUTICS LTD. (Exact name of registrant ...